T1	Participants 456 494	206 patients with locally advanced NPC
T2	Participants 623 631	patients
T3	Participants 782 818	59% of patients in the cisplatin arm
T4	Participants 516 536	101 to cisplatin arm
T5	Participants 541 563	105 to carboplatin arm
T6	Participants 890 917	73% in the carboplatin arm.
T7	Participants 1106 1122	cisplatin group,
T8	Participants 1156 1172	carboplatin arm.
T9	Participants 1217 1246	63.4% for the cisplatin group
T10	Participants 1251 1282	60.9% for the carboplatin group
T11	Participants 1385 1438	77.7% and 79.2% for cisplatin and carboplatin groups,
